Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement
Heart failure with reduced ejection fraction (HFrEF) is a debilitating disease that is associated with substantial morbidity, mortality, and societal costs. The past three decades have brought about significant advancements in the pharmacologic management of HFrEF, and a corresponding reduction in m...
Saved in:
Main Authors: | Bruce A. Warden (Author), Johannes Steiner (Author), Albert Camacho (Author), Khoa Nguyen (Author), Jonathan Q Purnell (Author), P. Barton Duell (Author), Courtney Craigan (Author), Diane Osborn (Author), Sergio Fazio (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice
by: Bruce A. Warden, et al.
Published: (2021) -
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022) -
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
by: Bruce A. Warden, et al.
Published: (2020) -
Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021) -
Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017)